Acinetobacter baumannii produces carbapenemase-hydrolyzing class D β-lactamases (CHDLs) as one of the major drug resistance mechanisms. This investigation is thus aimed to assess the prevalence and to characterize the CHDL-producing strains of A. baumannii by both phenotypic assays and genotypic characterization. A total of 73 isolates of A. baumannii were phenotypically and genotypically characterized from patients (N = 1,000) with severe urinary tract infection. Tested strains were subjected to double disk synergy testing by Kirby–Bauer disk diffusion method with modified Hodge test (MHT) for carbapenemase production. Plasmid DNA was molecularly screened for CHDL-encoding blaoxa-51, blaoxa-23, and blaoxa-143 genes by polymerase chain reaction. Carbapenem-resistant profile showed 100%, 61.64%, and 67.12% resistance by Kirby–Bauer disk diffusion method that correlated with MHT positivity for 100% (n = 73), 80% (n = 36), and 78% (n = 38) of the isolates against imipenem, doripenem, and meropenem, respectively. The blaoxa-51 and blaoxa-23 were observed in 41.09% (n = 30) and 35.61% (n = 26) with co-occurrence in 4.10% (n = 3) of the isolates. MHT-positive isolates showed 100%, 91.66%, and 71.4% for blaoxa-51 and 91.78%, 51.11%, and 34.69% for blaoxa-23 with imipenem, doripenem, and meropenem resistance, respectively. None of the strains yielded blaoxa-143 gene. The findings of this study showed prevalence of carbapenem resistance and high frequency of blaoxa-51 and blaoxa-23 among A. baumannii.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Berezin, E. B., Towner, K. J.: Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9, 148–165 (1996).
-
2.
Talbot, G. H., Bradley, J., Edwards, J. E., Gilbert, D.: Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42, 657–668 (2006).
-
3.
Dijkshoorn, L., Nemec, A., Seifert, H.: An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5, 939–951 (2007).
-
4.
Richet, H. M., Mohammed, J., McDonald, L. C.: Building communication networks: International network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 7, 319–322 (2000).
-
5.
Poirel, L., Bonnin, R. A., Nordmann, P.: Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life 63, 1061–1067 (2011).
-
6.
Smiline Girija, A. S., Vijayashree Priyadharsini, J., Paramasivam, A.: Prevalence of VIM and GIM producing Acinetobacter baumannii from patients with severe UTI. Acta Microbiol Immunol Hung 65, 539–550 (2018).
-
7.
Higgins, P. G., Dammhayn, C., Hackel, M., Seifert, H.: Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 65, 233–238 (2010).
-
8.
Poirel, L., Naas, T., Nordmann, P.: Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 54, 24–38 (2010).
-
9.
Woodford, N., Ellington, M. J., Coelho, J. M., Turton, J. F.: Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27, 351–353 (2006).
-
10.
Higgins, P. G., Lehmann, M., Seifert, H.: Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 35, 305–312 (2010).
-
11.
Poirel, L., Nordmann, P.: Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clin Microbiol Infect 12, 826–836 (2006).
-
12.
Nordmann, P., Poirel, L.: Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 8, 321–331 (2002).
-
13.
Clinical Laboratory Standards Institute [CLSI]: Performance Standards for Antimicrobial Susceptibility Testing. Table 3A: M02-A12 and M07-A10. CLSI, Wayne, PA, 2012.
-
14.
Srinivasa, V. B., Rajamohan, G., Pancholi, P., Stevenson, K., Tadesse, D., Patchanee, P., Marcon, M., Gebreyes, W. A.: Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA Gebreyes. Ann Clin Microbiol Antimicrob 8, 21–26 (2009).
-
15.
Smiline Girija, A. S., Vijayashree Priyadharsini, J., Paramasivam, A.: CLSI based antibiogram profile and the detection of MDR and XDR strains of Acinetobacter baumannii isolated from urine samples. Med J Islamic Rep Iran 33, 11–16 (2019).
-
16.
Yang, H. Y., Lee, H. J., Suh, J. T., Lee, K. M.: Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 β-lactamase in a tertiary care hospital in Korea. Yonsei Med J 50, 764–70 (2009).
-
17.
Andriamanantena, T. S., Ratsima, E., Rakotonirina, H. C., Randrianirina, F., Carod, J. F., Richard, V., Talarmin, A.: Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar. Ann Clin Microbiol Antimicrob 9, 17–23 (2010).
-
18.
Maleki, M. H., Sekawi, Z., Soroush, S., Azizi-Jalilian, F.: Phenotypic and genotypic characteristics of tetracycline resistant Acinetobacter baumannii isolates from nosocomial infections at Tehran hospitals. Iran J Basic Med Sci 17, 21–26 (2014).
-
19.
Tacconelli, E., Magrini, N.: Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available at http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1
-
20.
Sinha, M., Srinivasa, H.: Mechanisms of resistance to carbapenems in meropenem resistant Acinetobacter isolates from clinical samples. Indian J Med Microbiol 25, 121–125 (2007).
-
21.
Terzi, H. A., Atasoy, A. R., Aykan, S. B., Karakece, E., Asık, G., Ciftci, I. H.: Association of doripenem resistance with OXA-type carbapenemases in Acinetobacter baumannii isolates. Saudi Med J 37, 43–47 (2016).
-
22.
Goyal, K., Gautam, V., Ray, P.: Doripenem vs meropenem against Pseudomonas and Acinetobacter. Indian J Med Microbiol 30, 350–351 (2012).
-
23.
Hussein, H. N., Al-Mathkhury, J. F., Sabbah, A. M.: Imipenem resistant Acinetobacter baumannii isolated from patients and hospitals environment in Baghdad. Iraq J Sci 54, 803–812 (2013).
-
24.
Daef, E. A., Mohamed, I. S., Ahmed, A. S., El-Gendy, S. G.: Detection of outbreak caused by multidrug resistant Acinetobacter baumannii in Assiut University Hospitals. Afr J Microbiol Res 8, 2238–2244 (2014).
-
25.
Taneja, N., Maharwal, S., Sharma, M.: Imipenem resistance in non-fermenters causing nosocomial urinary tract infections. Ind J Med Sci 57, 294–299 (2003).
-
26.
Esterly, J. S., Qi, C., Malczynski, M., Scheetz, M. H.: Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and blaOXA gene status. Pharmacotherapy 30, 354–360 (2010).
-
27.
Sousa, D., Castelo-Corral, L., Gutiérrez-Urb, J. M., Molina, F., Lopez-Calvi, B.: Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: Collateral damage or positive effect on hospital ecology? J Antimicrob Chemother 68, 1917–1925 (2013).
-
28.
Da Silva, G. J., Correia, M., Vita, C., Ribeiro, G.: Molecular characterization of blaIMP-5, a new integron-borne metallo-β-lactamase gene from an Acinetobacter baumannii nosocomial isolate in Portugal. FEMS Microbiol Lett 215, 33–39 (2002).
-
29.
Ellington, M. J., Kistler, J., Livermore, D. M., Woodford, N.: Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicrob Chemother 59, 321–322 (2007).
-
30.
Seward, R. J.: Detection of integrons in worldwide nosocomial isolates of Acinetobacter spp. Clin Microbiol Infect 5, 308–318 (1999).
-
31.
Sung, J. Y., Kwon, K. C., Park, J. W., Kim, Y. S.: Dissemination of IMP-1 and OXA type -lactamase in carbapenem-resistant Acinetobacter baumannii. Korean J Lab Med 28, 16–23 (2008).
-
32.
Limansky, A. S., Mussi, M. A., Viale, A. M.: Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol 40, 4776–4778 (2002).
-
33.
Afzal-Shah, M., Woodford, N., Livermore, D. M.: Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 45, 583–588 (2001).
-
34.
Bou, G., Oliver, A., Martınez-Beltra, J.: OXA-24, a novel class D β-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 44, 1556–1561 (2000).
-
35.
Amudhan, S. M., Sekar, U., Arunagiri, K., Sekar, B.: OXA beta-lactamase-mediated carbapenem resistance in Acinetobacter baumannii. Ind J Med Microbiol 29, 269–274 (2011).
-
36.
Joshi, P. R., Acharya, M., Kakshapati, T., Leungtongkam, U.: Co-existence of blaOXA-23 and blaNDM-1 genes of Acinetobacter baumannii isolated from Nepal: Antimicrobial resistance and clinical significance. Antimicrob Resist Infect Control 6, 21–25 (2017).
Please, download the file from HERE
Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary
Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- Chemical Abstracts
- Global Health
- Index Medicus
- Index Veterinarius
- Medline
- Referativnyi Zhurnal
- SCOPUS
- Science Citation Index Expanded
| 2020 | |
| Total Cites | 662 |
| WoS | |
| Journal Impact Factor |
2,048 |
| Rank by | Immunology 145/162(Q4) |
| Impact Factor | Microbiology 118/137 (Q4) |
| Impact Factor | 1,904 |
| without | |
| Journal Self Cites | |
| 5 Year | 0,671 |
| Impact Factor | |
| Journal | 0,38 |
| Citation Indicator | |
| Rank by Journal | Immunology 146/174 (Q4) |
| Citation Indicator | Microbiology 120/142 (Q4) |
| Citable | 42 |
| Items | |
| Total | 40 |
| Articles | |
| Total | 2 |
| Reviews | |
| Scimago | 28 |
| H-index | |
| Scimago | 0,439 |
| Journal Rank | |
| Scimago | Immunology and Microbiology (miscellaneous) Q4 |
| Quartile Score | Medicine (miscellaneous) Q3 |
| Scopus | 438/167=2,6 |
| Scite Score | |
| Scopus | General Immunology and Microbiology 31/45 (Q3) |
| Scite Score Rank | |
| Scopus | 0,760 |
| SNIP | |
| Days from | 225 |
| submission | |
| to acceptance | |
| Days from | 118 |
| acceptance | |
| to publication | |
| Acceptance | 19% |
| Rate |
| 2019 | |
|---|---|
| Total Cites WoS |
485 |
| Impact Factor | 1,086 |
| Impact Factor without Journal Self Cites |
0,864 |
| 5 Year Impact Factor |
1,233 |
| Immediacy Index |
0,286 |
| Citable Items |
42 |
| Total Articles |
40 |
| Total Reviews |
2 |
| Cited Half-Life |
5,8 |
| Citing Half-Life |
7,7 |
| Eigenfactor Score |
0,00059 |
| Article Influence Score |
0,246 |
| % Articles in Citable Items |
95,24 |
| Normalized Eigenfactor |
0,07317 |
| Average IF Percentile |
7,690 |
| Scimago H-index |
27 |
| Scimago Journal Rank |
0,352 |
| Scopus Scite Score |
320/161=2 |
| Scopus Scite Score Rank |
General Immunology and Microbiology 35/45 (Q4) |
| Scopus SNIP |
0,492 |
| Acceptance Rate |
16% |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Publication Model | Online only Hybrid |
| Submission Fee | none |
| Article Processing Charge | 1100 EUR/article |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2022 | Online subsscription: 662 EUR / 832 USD Print + online subscription: 740 EUR / 930 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Acta Microbiologica et Immunologica Hungarica | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
1954 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1217-8950 (Print) |
| ISSN | 1588-2640 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Sep 2021 | 9 | 0 | 0 |
| Oct 2021 | 15 | 1 | 1 |
| Nov 2021 | 20 | 0 | 0 |
| Dec 2021 | 21 | 2 | 2 |
| Jan 2022 | 36 | 4 | 3 |
| Feb 2022 | 28 | 0 | 0 |
| Mar 2022 | 4 | 1 | 1 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory